By Healthcare Edge Editorial Staff Eterna Therapeutics Inc. (Nasdaq: ERNA) said it appointed Sanjeev Luther as incoming President and Chief Executive Officer from Jan. 1, 2024. Mr. Luther emphasized his commitment to advancing the reach and promise of mRNA cell...

By Healthcare Edge Editorial Staff ProSomnus, Inc. (NASDAQ: OSA), a pioneer in non-CPAP Obstructive Sleep Apnea (OSA) therapy, has revealed that its precision oral appliance therapy (OAT) devices effectively treat OSA, according to a study published by the Cureus Journal...

By Thomas S. Green Apollomics Inc. (Nasdaq: APLM) said it saw strong results from two clinical trials for Vebreltinib, designed to target non-small cell lung cancer and other advanced tumors. The trials showed that patients without co-occurring MET amplification had...

By Healthcare Edge Editorial Staff Octave Bioscience, Inc. said Founder William Hagstrom will become Chairman of the Board, while Doug Biehn is the new President and CEO. Mr. Biehn has over 20 years of experience in healthcare, building and scaling...

    By Healthcare Edge Editorial Staff SAB Biotherapeutics, Inc. (Nasdaq: SABS), which is trying to slow down the progression of type 1 diabetes, said it started trials of SAB-142 on humans in Australia. SAB-142 is the first fully-human anti-thymocyte...

Healthcare Edge and Exec Edge are please to provide complete video coverage of the third annual Palm Beach CorpGov Forum, which was held on Nov. 8, featuring a full day of panels and fireside chats. The event was composed of over...

By Karen E. Roman Alladapt Immunotherapeutics, Inc., a biopharmaceutical company developing treatment for Immunoglobulin E-mediated food allergy, said it received fast track designation by the U.S. Food and Drug Administration for ADP101, its multi-food oral immunotherapy. ADP101 is designed to...

    By Healthcare Edge Editorial Staff Octave Bioscience, Inc., a company offering treatment for multiple sclerosis and other neurodegenerative diseases, said it has received a $10 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The...

  By Karen E. Roman SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage company developing a fully-human treatment to delay the progress of type 1 diabetes, said its net loss narrowed in the third quarter. The net loss was $5.1 million,...

  By Karen E. Roman Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a company which develops biologic medicines, announced it has appointed Dorothy Clarke to its board of directors. Ms. Clarke previously held leadership roles at Johnson & Johnson for...